ArticleBMC ophthalmology2025
Early prediction of retinopathy of prematurity using targeted metabolomic profiling of 6-hydroxymethylpterin in preterm infants.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sigma 1 Receptor Activation Coordinates Metabolic Stress Responses to Protect Retinal Vasculature in Ischemic Retinopathy.Investigative ophthalmology & visual science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Retinopathy of prematurity (ROP) is a preventable cause of childhood blindness in extremely preterm infants, yet early biomarkers are lacking. In this pilot study, we utilized targeted metabolomic profiling of blood samples to measure plasma 6-hydroxymethylpterin (6PTC) levels in 18 preterm neonates. Results showed significantly higher 6PTC levels in infants who developed ROP compared to those who did not (p = 0.035), with receiver-operating characteristic analysis yielding an AUC of 0.831. These findings suggest that 6PTC may serve as a non-invasive early biomarker reflecting oxidative stress in ROP. However, the modest sample size warrants further validation in larger, longitudinal cohorts. Given the limited sample size, these results should be interpreted within the context of a pilot, hypothesis-generating study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.